Per Albertsson

Per Albertsson

Auto-generated profile, based on publicly available information

Per Albertsson

Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2003 in Trends in Immunology
Verified
Journal Article
Closed access
PAPer A. Albertsson
Per A. Albertsson
PBPer H. Basse
Per H. Basse
MHMarianne Hokland
Marianne Hokland
RGRonald H. Goldfarb
Ronald H. Goldfarb
JNJ.Fred Nagelkerke
J.Fred Nagelkerke
Peter KuppenPeter Kuppen
Peter Kuppen

1 January 2014 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
JEJörgen Elgqvist
Jörgen Elgqvist
SFSofia Frost
Sofia Frost
JPJean-Pierre Pouget
Jean-Pierre Pouget
PAPer Albertsson
Per Albertsson
This article presents a general discussion on what has been achieved so far and on the possible future developments of targeted alpha (α)-particle therapy (TAT). Clinical applications and potential benefits of TAT are addressed as well as the drawbacks, such as the limited availability of relevant radionuclides. Alpha-particles have a particular advantage in targeted therapy because of their high potency and specificity. These features are due to their densely ionizing track structure and short path length. The most important consequence, and the major difference compared with the more widely used β–-particle emitters, is that single targeted cancer cells can be killed by self-irradiation with α-particles. Several clinical trials on TAT have been reported, completed, or are on-going: four using 213Bi, two with 211At, two with 225Ac, and one with 212Pb/212Bi. Important and conceptual proof-of-principle of the therapeutic advantages of α-particle therapy has come from clinical studies with 223Ra-dichloride therapy, showing clear benefits in castration-resistant prostate cancer, and has recently been approved by the Food and drug Administration (FDA).

24 January 2018 in Medical Physics
Verified
Journal Article
Open access
PDF file
TNTufve Nyholm
Tufve Nyholm
SSStina Svensson
Stina Svensson
SASebastian Andersson
Sebastian Andersson
JJJoakim Jonsson
Joakim Jonsson
MSMaja Sohlin
Maja Sohlin
AGAdalsteinn Gunnlaugsson
Adalsteinn Gunnlaugsson
Purpose: We describe a public dataset with MR and CT images of patients performed in the same position with both multiobserver and expert consensus delineations of relevant organs in the male pelvic region. The purpose was to provide means for training and validation of segmentation algorithms and methods to convert MR to CT like data, i.e., so called synthetic CT (sCT).Acquisition and validation methods: T1‐ and T2‐weighted MR images as well as CT data were collected for 19 patients at three different departments. Five experts delineated nine organs for each patient based on the T2‐weighted MR images. An automatic method was used to fuse the delineations. Starting from each fused delineation, a consensus delineation was agreed upon by the five experts for each organ and patient. Segmentation overlap between user delineations with respect to the consensus delineations was measured to describe the spread of the collected data. Finally, an open‐source software was used to create deformation vector fields describing the relation between MR and CT images to further increase the usability of the dataset.Data format and usage notes: The dataset has been made publically available to be used for academic purposes, and can be accessed from https://zenodo.org/record/583096.Potential applications: The dataset provides a useful source for training and validation of segmentation algorithms as well as methods to convert MR to CT‐like data (sCT). To give some examples: The T2‐weighted MR images with their consensus delineations can directly be used as a template in an existing atlas‐based segmentation engine; the expert delineations are useful to validate the performance of a segmentation algorithm as they provide a way to measure variability among users which can be compared with the result of an automatic segmentation; and the pairwise deformably registered MR and CT images can be a source for an atlas‐based sCT algorithm or for validation of sCT algorithm.

6 January 2023 in Frontiers in Medicine
Verified
Journal Article
Open access
PAPer Albertsson
Per Albertsson
TBTom Bäck
Tom Bäck
KBKarin Bergmark
Karin Bergmark
AHAndreas Hallqvist
Andreas Hallqvist
MJMia Johansson
Mia Johansson
SPStig Palm
Stig Palm
Astatine-211 (211At) has physical properties that make it one of the top candidates for use as a radiation source for alpha particle-based radionuclide therapy, also referred to as targeted alpha therapy (TAT). Here, we summarize the main results of the completed clinical trials, further describe ongoing trials, and discuss future prospects.

1 February 2005 in Molecular Immunology
Verified
Journal Article
Closed access
MSM.H. Sandel
M.H. Sandel
FSF.M. Speetjens
F.M. Speetjens
AMA.G. Menon
A.G. Menon
PAP.A. Albertsson
P.A. Albertsson
PBP.H. Basse
P.H. Basse
Peter KuppenPeter Kuppen
Peter Kuppen

25 January 2019 in Journal of Nuclear Medicine
Verified
Journal Article
Closed access
PDF file
AHAndreas Hallqvist
Andreas Hallqvist
KBKarin Bergmark
Karin Bergmark
TBTom Bäck
Tom Bäck
HAHåkan Andersson
Håkan Andersson
PDPernilla Dahm-Kähler
Pernilla Dahm-Kähler
PAPer Albertsson
Per Albertsson
Eliminating microscopic residual disease with α-particle radiation is theoretically appealing. After extensive preclinical work with α-particle–emitting 211At, we performed a phase I trial with intraperitoneal α-particle therapy in epithelial ovarian cancer using 211At conjugated to MX35, the antigen-binding fragments—F(ab′)2—of a mouse monoclonal antibody. We now present clinical outcome data and toxicity in a long-term follow-up with individual absorbed dose estimations. Methods: Twelve patients with relapsed epithelial ovarian cancer, achieving a second complete or nearly complete response with chemotherapy, received intraperitoneal treatment with escalating (20–215 MBq/L) activity concentrations of 211At-MX35 F(ab′)2. Results: The activity concentration was escalated to 215 MBq/L without any dose-limiting toxicities. Most toxicities were low-grade and likely related to the treatment procedure, not clearly linked to the α-particle irradiation, with no observed hematologic toxicity. One grade 3 fatigue and 1 grade 4 intestinal perforation during catheter implantation were observed. Four patients had a survival of more than 6 y, one of whom did not relapse. At progression, chemotherapy was given without signs of reduced tolerability. Overall median survival was 35 mo, with a 1-, 2-, 5-, and 10-y survival of 100%, 83%, 50%, and 25%, respectively. Calculations of the absorbed doses showed that a lower specific activity is associated with a lower single-cell dose, whereas a high specific activity may result in a lower central dose in microtumors. Individual differences in absorbed dose to possible microtumors were due to variations in administered activity and the specific activity. Conclusion: No apparent signs of radiation-induced toxicity or decreased tolerance to relapse therapy were observed. The dosimetric calculations show that further optimization is advisable to increase the efficacy and reduce possible long-term toxicity.